- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01926054
ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
An Open Label Randomized Phase IV Study of the Safety and Efficacy of ACTHAR GEL in Patients With Membranous (Class V) Lupus Nephritis
This is an open-label, randomized, multi-center, Phase IV study of Acthar Gel in patients with biopsy-proven membranous (Class V) lupus nephritis (LN) aimed at providing proof-of-concept data that Acthar is a safe and effective therapy for membranous LN. Class V LN is a secondary form of membranous nephropathy, and occurs in 8-20% of patients with LN.
Two different doses of Acthar Gel will be tested. The active intervention phase of this study will take place over 6 months, and follow-up will occur over the following 6 months. Efficacy and safety of the use of Acthar Gel for treatment of membranous LN will be assessed and analyzed throughout the course of the study by laboratory testing, physical exams, and other evaluation tools. Subjects will be closely monitored for adverse effects associated with the use of Acthar gel and if necessary study drug dosing will be reduced. The anticipated benefits to subjects are a complete renal response rate of 40% at 6 months showing superiority over the published complete remission rates of the currently used immunosuppressive therapies, and no unexpected toxicity signals.
Pure Class V LN affects a significant number of systemic lupus erythematosus (SLE) patients and although it is less aggressive than proliferative forms of LN it still causes important renal and non-renal morbidity and mortality over time, especially in patients who remain nephrotic. The therapy of Class V LN is not clear, and currently used therapies are highly toxic because of immunosuppression, risk of infertility, and risk of future malignancy. Additionally, these therapies are only modestly effective in inducing remissions of Class V LN. There is thus an unmet need for a more effective and less toxic treatment for Class V LN.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- The Ohio State University Wexner Medical Center, Nephrology Clinical Trials Unit
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients ≥ 18 years of age who have pure Class V LN or Class V+II LN diagnosed by a kidney biopsy within 4 months of screening. If a patient has segmental glomerular scarring indicative of previous Class III or IV lesions, but no evidence of current Class III or IV activity, and only the Class V component is active, they can be enrolled, despite having a mandatory ISN/RPA classification of Class V + III or IV
- Proteinuria ≥ 3 g/d despite adequate blood pressure control defined as systolic blood pressure ≤ 130 mm Hg 75% of the time, per the clinical judgment of the site investigator.
- Serum creatinine < 2 mg/dl or eGFR > 30 ml/minute
Exclusion Criteria:
Patients < 18 years of age
- Pregnancy or planning to become pregnant anytime throughout their participation in the trial, up until 30 days after last dose of study drug.
- Kidney biopsy with active Class III or IV LN
- More than 50% interstitial fibrosis and/or glomerulosclerosis on kidney biopsy
- Patients with hepatitis B, C, HIV, TB or other active and chronic infections at the time of screening
- Patients with liver disease and transaminases greater than 2.5 times the upper limit of normal of the laboratory, patients with diabetes mellitus type I or II, patients with refractory hypokalemia, patients with Cushing's Disease or Syndrome
- Patients who have been treated with cyclophosphamide, cyclosporine A, tacrolimus, B-cell depleting therapies, or experimental therapies including biologics within 6 months of screening
- Patients with active neuropsychiatric lupus, lupus pneumonitis, lupus vasculitis at screening
- Patients with high or very high extra-renal lupus activity defined as an xSLEDAI score greater than 10 at the time of screening
- Patients who have received high-dose intravenous methylprednisolone (1 g cumulative) within 3 months of screening
- Patients currently receiving, or who have received MMF or AZA in the 3 months preceding enrollment for extra-renal SLE.
- Patients who have received methotrexate or who are receiving methotrexate and it can be discontinued will be eligible; if methotrexate cannot be stopped safely, the patient will not be eligible.
- Patients currently receiving more than 20 mg/d prednisone that cannot be safely reduced to 20mg/d or less beginning at least one month before enrollment on day 0
- Patients who are not on a stable dose of Anti-Malarials and/or Anti-hypertensives at least one month preceding baseline visit and during the study. (Refer to allowed medication section)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Acthar Gel 80 IU SC BIW
80 IU administered subcutaneously BIW for 6 months
|
|
Active Comparator: Acthar Gel 80 IU SC TIW
80 IU administered subcutaneously TIW for 6 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: Baseline and Month 12
|
Measuring adverse events and serious adverse events taking Acthar Gel in Class V lupus nephritis
|
Baseline and Month 12
|
Change in laboratory data
Time Frame: Baseline and Month 12
|
changes in laboratory parameters, and metabolic side effects such as hyperglycemia, hypokalemia, and hyperlipidemia
|
Baseline and Month 12
|
Renal Response to Acthar Gel
Time Frame: Baseline and Month 6
|
Change in Proteinuria and serum creatinine
|
Baseline and Month 6
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in remission
Time Frame: Month 6 and Month 12
|
To determine the duration of complete and partial remission after study drug is stopped
|
Month 6 and Month 12
|
Change baseline SLE laboratory
Time Frame: Baseline and month 6
|
To determine the effect of Acthar Gel on baseline levels of anti-double stranded DNA (dsDNA) antibodies and complement components C3 and C4
|
Baseline and month 6
|
Change in extra-renal systemic lupus erythematosus disease activity index
Time Frame: Baseline and Month 6
|
To determine the effect of Acthar Gel on the patients global assessment score, the physicians global assessments score and xSLEDAI
|
Baseline and Month 6
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
reduction of urine protein to creatinine ratio
Time Frame: week 8 and month 6
|
To determine if a reduction of the urine protein-to-creatinine ratio (uPCR) of an intended 24-hour of ≥25% at 8 weeks predicts complete or partial response at 6 months
|
week 8 and month 6
|
change urine monocyte chemotactic protein-1 and urine vascular endothelial growth factor
Time Frame: Baseline and 6 month
|
To determine change from baseline of urine monocyte chemotactic protein-1 (uMCP1) and urine vascular endothelial growth factor (uVEGF) at 3 and 6 months
|
Baseline and 6 month
|
percent of patients who have renal and non renal flares
Time Frame: baseline and month 12
|
To determine the % of patients who have renal flares during treatment and during follow-up
|
baseline and month 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Brad H Rovin, MD, The Ohio State University Wexner Medical Center, Division of Nephrology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2013H0121
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SLE Glomerulonephritis Syndrome, WHO Class V
-
Kyverna TherapeuticsRecruitingLupus Nephritis | Lupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class IIIGermany
-
Artiva Biotherapeutics, Inc.RecruitingLupus Nephritis - WHO Class IV | Lupus Nephritis - WHO Class IIIUnited States
-
Kyverna TherapeuticsRecruitingLupus Nephritis | Lupus Nephritis - World Health Organization (WHO) Class III | Lupus Nephritis - WHO Class IVUnited States
Clinical Trials on Acthar gel
-
Tanner Foundation for Multiple SclerosisMallinckrodt; Auburn University MRI Research Center; iReportoire IncUnknown
-
Mayo ClinicMallinckrodtCompletedProteinuria | Progressive IgA NephropathyUnited States
-
Ocular Immunology and Uveitis FoundationUnknownUveitis, Posterior | Vasculitis RetinalUnited States
-
MallinckrodtCompletedArthritis, RheumatoidUnited States, Puerto Rico, Mexico, Peru, Argentina
-
Stanford UniversityMallinckrodtCompletedKidney DiseasesUnited States
-
University of MinnesotaMallinckrodtTerminatedPrimary Progressive Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
University of Maryland, BaltimoreMallinckrodtCompleted
-
Mayo ClinicMallinckrodtCompletedIdiopathic Membranous NephropathyUnited States, Canada
-
The Cleveland ClinicMallinckrodtCompletedDermatomyositis | Juvenile DermatomyositisUnited States
-
Fiechtner, Justus J., M.D., P.C.CompletedLupus Erythematosus Systemic ExacerbationUnited States